Cipla Q2 FY24 Results: Consolidated PAT Rises to Rs. 1,130.91 Cr

Cipla Q2 FY24 Results: Consolidated PAT Rises to Rs. 1,130.91 Cr

Cipla Q2 FY24 Results Today

Cipla Q2 results show revenue up from 6,465.18 crores to 6,854.47 crores, a 6.02% increase in growth. EPS rose from ₹12.34 to ₹14.01, up by 13.53%.

Quarter-on-Quarter Basis Results (Q2 FY2024):

Cipla shared its Q2 results on Friday. They earned 6,854.47 crores in revenue this quarter, but that’s more than the 6,465.18 crores they made last quarter. The company’s growth increased by 6.02 percent when comparing the two quarters.

In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 1,130.91 crores, up from 995.70 crores in the previous quarter. Their quarter-to-quarter growth increased by 13.58 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹14.01, which is an increase of 13.53% from the ₹12.34 EPS in the previous quarter.

Year-over-Year Basis Results (Q2 FY2024):

The company made a total revenue of 6,854.47 crores this year (2023), which is 15.17 percent higher than last year’s total revenue of 5,951.49 crores.

This year’s PAT (Profit After Tax) is 1,130.91 crores, which is also 43.35% higher than last year’s PAT of 788.90 crores.

The EPS (Earnings Per Share) for this year is ₹14.01, which is 43.25% more than the EPS of ₹9.78 earned last year.

Year-over-Year Basis Results (Half Year Ended FY2024):

In the first half of 2023, the company generated a total revenue of 13,319.65 crores, marking a 16.53% increase compared to the previous year’s 11,430.11 crores.

The PAT (Profit After Tax) for this half-year stands at 2,126.61 crores, showing a 44.15% growth over the previous year’s 1,475.30 crores.

The EPS (Earnings Per Share) for this half-year is ₹26.34, representing a 44.09% increase from the previous half-year’s EPS of ₹18.28.

Cipla Share Dividend Announcement / Record Date:

The record date for the dividend has not arrived yet.

About Cipla:

Cipla is a global pharmaceutical corporation specializing in the research and production of medications. Its central offices are situated in Mumbai, India. The company conducts business in various regions, including India, the United States, Canada, and South Africa, as well as both regulated and emerging markets worldwide.

Download the Full PDF of Q2 Results: Click Here

For more of the Latest News, Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *